Cas:141109-15-1 (S)-(+)-2-Chlorophenylglycine methyl ester hydrochloride manufacturer & supplier

Chemical Name:(S)-(+)-2-Chlorophenylglycine methyl ester hydrochloride

CAS.NO:141109-15-1

Synonyms:(+)-2-chlorophenyl glycine methyl ester tartrate salt;Piperidinium,2-carboxy-1,1-dimethyl-,chloride;(+-)-2-carboxy-1,1-dimethyl-piperidinium,chloride;(alphaS)-alpha-Amino-2-chloro-benzeneacetic acid methyl ester (2R,3R)-2,3-dihydroxybutanedioate;(S)-(+)-2-Chlorophenylglycine methyl ester hydrochloride

Molecular Formula:C₉H₁₁Cl₂NO₂

Molecular Weight:236.09500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:38.33000

Exact Mass:235.01700

LogP:2.79990

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (+)-2-chlorophenyl glycine methyl ester tartrate salt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(S)-(+)-2-Chlorophenylglycine methyl ester hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(+-)-2-carboxy-1,1-dimethyl-piperidinium,chloride Use and application,(+-)-2-carboxy-1,1-dimethyl-piperidinium,chloride technical grade,usp/ep/jp grade.

Related News: Rates of breast cancer-related genetic mutations in Black and white women are the same, according to a new study that contradicts previous research. (S)-(+)-2-Chlorophenylglycine methyl ester hydrochloride manufacturer China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement. (S)-(+)-2-Chlorophenylglycine methyl ester hydrochloride supplier Rates of breast cancer-related genetic mutations in Black and white women are the same, according to a new study that contradicts previous research. (S)-(+)-2-Chlorophenylglycine methyl ester hydrochloride vendor Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. (S)-(+)-2-Chlorophenylglycine methyl ester hydrochloride factory Rates of breast cancer-related genetic mutations in Black and white women are the same, according to a new study that contradicts previous research.